| Group A* (CD4 <100 cells/μl) (n = 33) | Group B* (CD4 = 100–200 cells/μl) (n = 13) | Group C* (CD4 >200 cells/μl) (n = 17) | Total* (n = 63) | |||||
| Jan 1998– Jan 2005 (n = 22) | Feb 2005–Oct 2007 (n = 11) | Jan 1998–Jan 2005 (n = 7) | Feb 2005–Oct 2007 (n = 6) | Jan 1998– Jan 2005 (n = 13) | Feb 2005– Oct 2007 (n = 4) | Jan 1998– Jan 2005 (n = 41) | Feb 2005– Oct 2007 (n = 22) | |
| Patient determined reasons | ||||||||
| Patient declined ART | 3 (13.6%) | 4 (28.6%) | 1 (14.3%) | 1 (11.1%) | 3 (21.4%) | 2 (50%) | 7 (16.3%) | 7 (25.9%) |
| Fear of side effects from ART | 1 (4.5%) | 1 (7.1%) | 0 (0%) | 1 (11.1%) | 0 (0%) | 0 (0%) | 1 (2.3%) | 2 (7.4%) |
| Chaotic clinic attendance/poor adherence with ATT | 2 (9.1%) | 1 (7.1%) | 1 (14.3%) | 0 (0%) | 3 (21.4%) | 0 (0%) | 6 (13.9%) | 1 (3.7%) |
| Physician determined reasons | ||||||||
| Grade III/IV ADR to ATT | 6 (27.3%) | 2 (14.3%) | 2 (28.6%) | 2 (22.2%) | 0 (0%) | 0 (0%) | 8 (18.6%) | 4 (14.8%) |
| Fear of toxicity/IRIS | 4 (18.2%) | 2 (14.3%) | 0 (0%) | 1 (11.1%) | 0 (0%) | 0 (0%) | 4 (9.3%) | 3 (11.1%) |
| Good CD4, ART not considered by physician | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 3 (21.4%) | 2 (50%) | 3 (8.0%) | 2 (7.4%) |
| Intercurrent AIDS defining illness | 2 (9.1%) | 0 (0%) | 1 (14.3%) | 1 (11.1%) | 0 (0%) | 0 (0%) | 3 (7.0%) | 1 (3.7%) |
| Patient sick with tuberculosis | 1 (4.5%) | 3 (21.4%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (2.3%) | 3 (11.1%) |
| Prolonged initiation phase of ATT | 1 (4.5%) | 0 (0%) | 2 (28.6%) | 0 (0%) | 0 (0%) | 0 (0%) | 3 (7.0%) | 0 (0%) |
| Intercurrent infection | 1 (4.5%) | 1 (7.1%) | 0 (0%) | 1 (11.1%) | 0 (0%) | 0 (0%) | 1 (2.3%) | 2 (7.4%) |
| Other | 0 (0%) | 0 (0%) | 0 (0%) | 1 (11.1%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (3.7%) |
| Non-clinically-determined reasons | 1 (4.5%) | 0 (0%) | 0 (0%) | 1 (11.1%) | 5 (35.7%) | 0 (0%) | 6 (14.0%) | 1 (3.7%) |
| Total | 22 (100%) | 14 (100%) | 7 (100%) | 9 (100%) | 14 (100%) | 4 (100%) | 43 (100%) | 27 (100%) |
*Some patients had more than one reason for delay.
ADR, adverse drug reaction; ART, antiretroviral therapy; ATT, antituberculosis therapy; IRIS, immune reconstitution inflammatory syndrome.